```html

Kernicterus (Severe Neonatal Jaundice)

What is Kernicterus Jaundice?

Kernicterus, also called bilirubin‑induced neurological dysfunction (BIND), is a rare but serious complication of newborn jaundice. It occurs when high levels of unconjugated (indirect) bilirubin cross the blood‑brain barrier and deposit in the basal ganglia, brainstem nuclei, and cerebellum. The resulting neuro‑toxicity can cause permanent motor, auditory, and cognitive deficits.

In most infants, jaundice is harmless and resolves with simple treatments such as phototherapy. Kernicterus develops only when bilirubin rises rapidly or remains elevated for several days without adequate treatment. Early recognition and prompt management of neonatal jaundice are therefore essential to prevent this life‑changing condition.

Common Causes

While any newborn with severe hyperbilirubinemia is at risk, several underlying conditions make kernicterus more likely. The most common contributors are:

• Hemolytic disease of the newborn (HDN) – ABO or Rh incompatibility causing rapid red‑cell destruction.
• Breast‑feeding jaundice – Insufficient milk intake in the first days leads to dehydration and reduced bilirubin excretion.
• Breast‑feeding jaundice (milk‑induced) – Certain substances in breast‑milk (e.g., β‑glucuronidase) increase enterohepatic circulation of bilirubin.
• Genetic enzyme deficiencies – G6PD deficiency, hereditary spherocytosis, or pyruvate kinase deficiency accelerate hemolysis.
• Crigler‑Najjar syndrome type I – A rare inherited defect in UDP‑glucuronosyltransferase (UGT1A1) causing absent bilirubin conjugation.
• Physiologic prematurity – Preterm infants have immature liver enzymes and a more permeable blood‑brain barrier.
• Sepsis or severe infection – Inflammation impairs bilirubin uptake and conjugation.
• Acidosis and hypoxia – Conditions such as birth asphyxia increase bilirubin production and reduce clearance.
• Medications – Certain drugs (e.g., sulfonamides, (non‑steroidal) NSAIDs) can displace bilirubin from albumin.
• Genetic polymorphisms – Common UGT1A1 variants (e.g., Gilbert syndrome) lower conjugation capacity.

Associated Symptoms

Before neurological damage sets in, the infant usually shows classic signs of jaundice. As bilirubin climbs, additional systemic symptoms may appear:

• Yellow discoloration of the skin and sclera, starting at the head and progressing downwards.
• Lethargy or poor feeding – the baby may be unusually sleepy or weak.
• High‑pitched cry – a screeching cry can be an early sign of neuro‑toxicity.
• Hypotonia (floppy muscles) or, conversely, hypertonia (stiffness) in the limbs.
• Movement disorders such as opisthotonus (arched back) or choreoathetoid movements.
• Auditory deficits – infants may not startle to loud noises.
• Seizures – may be focal or generalized, heralding severe encephalopathy.
• Feeding difficulties – weak suck, inability to latch, or vomiting.

These neurological signs usually appear when total serum bilirubin (TSB) exceeds 20–25 mg/dL in term infants, but the threshold is lower in preterm babies.

When to See a Doctor

Because bilirubin can rise quickly, parents and caregivers should act promptly if any of the following occur:

• Yellowing of the skin that spreads from the face to the chest, abdomen, or limbs.
• Yellow coloration of the whites of the eyes (scleral icterus).
• Baby is unusually sleepy, hard to wake, or not feeding well.
• Any change in the infant’s cry – especially a high‑pitched, shrill sound.
• Muscle tone feels abnormal (either floppy or stiff).
• Seizures, tremors, or unexplained movements.
• Fever, poor weight gain, or signs of infection in the first week of life.

If you notice any of these signs, seek medical attention immediately. Early treatment can prevent bilirubin from reaching neurotoxic levels.

Diagnosis

Evaluation of possible kernicterus involves both laboratory tests and clinical assessment:

1. Laboratory Studies

• Serum total bilirubin (TSB) – measured via a heel‑stick or venous draw; the primary marker to guide therapy.
• Direct (conjugated) vs. indirect (unconjugated) bilirubin – kernicterus is related to very high indirect bilirubin.
• Blood type and Coombs test – to detect hemolytic disease.
• Complete blood count (CBC) & reticulocyte count – assess hemolysis.
• G6PD assay – if hemolysis is suspected.
• Serum albumin – low albumin increases free bilirubin.
• Blood gas and electrolytes – to rule out acidosis, which worsens bilirubin neuro‑toxicity.

2. Clinical Tools

• Transcutaneous bilirubinometer (TcB) – a non‑invasive skin scanner, useful for screening.
• American Academy of Pediatrics (AAP) nomograms – age‑specific bilirubin thresholds guide treatment decisions.
• Neurologic exam – assessment of tone, reflexes, and level of consciousness.

3. Imaging (if kernicterus is suspected)

• Brain MRI – shows characteristic T1 hyperintensity in the basal ganglia.
• Auditory brain‑stem response (ABR) testing – identifies early hearing loss.

Treatment Options

Management focuses on rapidly lowering serum bilirubin and preventing further bilirubin entry into the brain.

Phototherapy

• First‑line therapy for most cases of severe jaundice.
• Blue‑green light (≈460 nm) converts bilirubin into water‑soluble isomers that can be excreted without conjugation.
• Intensive double‑surface phototherapy is used when TSB approaches the exchange‑transfusion threshold.

Exchange Transfusion

• Indicated when bilirubin is dangerously high (>25 mg/dL in term infants) or when phototherapy fails.
• Whole blood is removed and replaced with compatible donor blood, rapidly reducing bilirubin and circulating antibodies.
• Risks include electrolyte imbalance, infection, and thrombocytopenia; performed in a NICU under close monitoring.

Intravenous Immunoglobulin (IVIG)

• Used for immune‑mediated hemolysis (e.g., Rh incompatibility) to block maternal antibodies.
• Can reduce the need for exchange transfusion when given early.

Supportive Care

• Ensuring adequate hydration and nutrition—frequent breastfeeding or expressed milk.
• Correcting underlying infections, metabolic acidosis, or hypoxia.
• Monitoring temperature, glucose, and electrolytes closely.

Long‑Term Management

• Children who have suffered kernicterus require multidisciplinary follow‑up: neurology, audiology, ophthalmology, and developmental pediatrics.
• Physical, occupational, and speech therapy help address motor and language delays.
• Early hearing amplification (hearing aids or cochlear implants) may be needed.

Prevention Tips

Most cases of kernicterus are preventable with vigilant newborn care:

• Early bilirubin screening – Obtain a baseline TSB or transcutaneous measurement before discharge (usually at 24‑48 h of age).
• Frequent feeding – Breastfeed ≥8‑12 times per 24 h or provide expressed milk to maintain hydration and promote bilirubin excretion.
• Follow‑up appointments – High‑risk newborns (preterm, ABO/Rh incompatibility, G6PD deficiency) need a pediatric visit within 2‑3 days after discharge.
• Watch for rapid weight loss – >10% loss in the first week warrants evaluation for dehydration and jaundice.
• Avoid medications that displace bilirubin – Notify clinicians of any new drug, especially sulfonamides or certain antibiotics.
• Prompt treatment of maternal conditions – Control diabetes and hypertension during pregnancy, which can increase neonatal jaundice risk.
• Educate caregivers – Distribute written material on how to recognize worsening jaundice and when to call the pediatrician.

Emergency Warning Signs

References

• Mayo Clinic. “Kernicterus.” https://www.mayoclinic.org.
• American Academy of Pediatrics. “Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation.” *Pediatrics* 2022; 149(6):e2022056970.
• World Health Organization. “Neonatal Jaundice: Guidelines for the Management of Hyperbilirubinemia.” WHO Publication, 2021.
• Cleveland Clinic. “Neonatal Jaundice.” https://my.clevelandclinic.org.
• National Institutes of Health, MedlinePlus. “Kernicterus.” https://medlineplus.gov.
• Shapiro SM, et al. “Bilirubin‑Induced Neurologic Dysfunction.” *New England Journal of Medicine*, 2020; 383:1592‑1603.

```